Nephrology

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.

Levy describes the goal of deploying mobile health units in Detroit to close gaps in CKD screening.

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.

Pranav discusses the necessity for addressing the structural barriers that remain for living donor kidney transplantations in black patients.

A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA.

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

A multicenter RCT of intradialytic cycling showed a modest, nonsignificant reduction in myocardial stunning in hemodialysis patients.

Davies explains the future of at-home dialysis access, including policy changes and technological innovation.

Catch up on nephrology headlines you missed from Q1 2026.

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN.

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan.

Catch up on the guideline updates, trial news, and featured content from March 2026.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Data presented at the World Congress of Nephrology highlight faster and higher rates of microscopic hematuria negativity with sibeprenlimab treatment.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Garimella discusses the history, clinical impact, and rationale for removing race-based GFR from clinical decision-making.

David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.

Martin de Borst, MD, PhD, discusses IV iron use in transplant recipients through an RCT focused on exercise capacity, function, and quality of life.

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

NEPTUNE and CureGN are advancing precision nephrology, linking molecular data to outcomes and enabling targeted therapies and smarter clinical trial design.

CAR-T therapy in lupus may shift earlier in care, but challenges in access, logistics, and patient selection remain as the field moves toward precision treatment.

FSGS recurrence threatens transplant success, yet clinicians still lack reliable predictors, mechanisms, and effective prevention strategies.